ストックスクリーナーアプリを入手
56.30
0.43%
0.226
前日終値:
$56.07
開ける：
$56.04
24時間の取引高:
306.31K
Relative Volume:
0.39
時価総額：
$3.50B
収益：
$45.48M
当期純損益:
$169.95M
株価収益率:
21.49
EPS:
2.62
ネットキャッシュフロー:
$230.85M
1週間 パフォーマンス:
+4.77%
1か月 パフォーマンス:
+1.50%
6か月 パフォーマンス:
+49.17%
1年 パフォーマンス:
+36.02%
1日の値動き範囲:
$55.51
$57.99
1週間の範囲:
$53.49
$57.99
52週間の値動き範囲:
$33.31
$60.60
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
56.28 | 3.49B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.63 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.33 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.62 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.53 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.07 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-12-06 | 開始されました | Goldman | Neutral |
| 2024-11-05 | 開始されました | Wedbush | Outperform |
| 2024-09-24 | 開始されました | TD Cowen | Buy |
| 2024-09-09 | 開始されました | Truist | Buy |
| 2023-10-30 | 開始されました | CapitalOne | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-24 | 開始されました | Northland Capital | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-12-16 | 開始されました | Piper Sandler | Overweight |
| 2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | 開始されました | Jefferies | Buy |
| 2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-09 | アップグレード | Stifel | Hold → Buy |
| 2018-12-06 | 開始されました | Nomura | Buy |
| 2018-01-29 | 開始されました | Stifel | Buy |
| 2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Protagonist (PTGX) Q2 Revenue Falls 26% - AOL.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates - 富途牛牛
Protagonist Therapeutics Inc. Approaches Psychological Resistance LevelQuarterly Profit Report & Weekly Hot Stock Watchlists - thegnnews.com
Protagonist Therapeutics’ SWOT analysis: biotech firm’s stock poised for growth - Investing.com Canada
Exploring High Growth Tech Stocks In The US Market - simplywall.st
Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot? - Yahoo Finance
Protagonist Therapeutics shares rise 3.78% intraday amid global geopolitical tensions. - AInvest
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Lansing State Journal
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Citi Analyst Maintains Buy Rating on Protagonist Therapeutics with $72.00 Price Target - AInvest
Protagonist Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Protagonist Therapeutics Completes Promising Phase 2 Study on PTG-300 for Polycythemia Vera - TipRanks
Protagonist Therapeutics’ Rusfertide Study: A Promising Update for Polycythemia Vera Treatment - TipRanks
Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability - TipRanks
Protagonist Therapeutics price target raised to $69 from $67 at Citizens JMP - TipRanks
Protagonist Therapeutics stock price target raised to $69 by JMP - Investing.com Canada
Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress - TipRanks
Protagonist (PTGX) Q2 Revenue Falls 26% - The Motley Fool
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
Protagonist Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Protagonist Therapeutics: Promising Developments in Rusfertide and Icotrokinra Drive Buy Rating - TipRanks
Protagonist Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Canada
Why Protagonist Therapeutics Shares Are Dropping - TipRanks
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Protagonist Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Protagonist Therapeutics Q2 net loss beats expectations - MarketScreener
Protagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus - TipRanks
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - MSN
Does Protagonist Therapeutics Inc. stock pay reliable dividendsHigh Growth Low Risk Stock Selection Gets Analyst Nod - beatles.ru
Why is Protagonist Therapeutics Inc. stock attracting strong analyst attentionStay ahead with daily expert stock picks - Jammu Links News
What drives Protagonist Therapeutics Inc. stock priceHigh-octane financial growth - Jammu Links News
Does Protagonist Therapeutics Inc. stock perform well during market downturnsFree Stock Index Interpretation - Jammu Links News
What is Protagonist Therapeutics Inc. company’s growth strategyRapid return acceleration - Jammu Links News
Is it the right time to buy Protagonist Therapeutics Inc. stockAchieve rapid wealth accumulation with smart picks - Jammu Links News
What is the dividend policy of Protagonist Therapeutics Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
Is Protagonist Therapeutics Inc. a growth stock or a value stockTremendous return on equity - Jammu Links News
What are the technical indicators suggesting about Protagonist Therapeutics Inc.Build wealth steadily with proven investment strategies - Jammu Links News
How does Protagonist Therapeutics Inc. compare to its industry peersHigh-octane investment gains - Jammu Links News
What catalysts could drive Protagonist Therapeutics Inc. stock higher in 2025Superior return velocity - Jammu Links News
How strong is Protagonist Therapeutics Inc. company’s balance sheetInvest confidently with professional market insights - Jammu Links News
Protagonist Therapeutics Inc. Stock Analysis and ForecastTriple-digit growth rates - Jammu Links News
What are analysts’ price targets for Protagonist Therapeutics Inc. in the next 12 monthsRapid wealth accumulation - Jammu Links News
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
Protagonist Therapeutics Inc (PTGX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| PATEL DINESH V PH D | President and CEO |
Jul 22 '25 |
Sale |
55.05 |
22,065 |
1,214,678 |
548,538 |
| PATEL DINESH V PH D | President and CEO |
Jul 23 '25 |
Sale |
54.79 |
17,520 |
959,921 |
531,018 |
| PATEL DINESH V PH D | President and CEO |
Jul 21 '25 |
Sale |
54.86 |
12,859 |
705,445 |
570,603 |
0.14%
0.30%
大文字化:
|
ボリューム (24 時間):